In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate Drug Master File in Korea (6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate. The MFDS reviews the 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF as part of the drug registration process and uses the information provided in the 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate suppliers with KDMF on PharmaCompass.